There is a strong basis for investigation of the therapeutic potential of ecadotril in chronic congestive heart failure (CHF). Currently, optimal medical treatment of CHF is founded upon digitalis, diuretics, and vasodilator drugs (Packer, 1993). Ecadotril shares with diuretic drugs the potential to counteract circulatory volume overload by means of its promotion of the natriuretic and aldosterone-antagonistic properties of endogenous natriuretic peptides. Ecadotril also shares the potential of direct-and-indirect-acting vasodilators to reverse the vasoconstriction which characterizes chronic CHF and which leads to inexorable decline in cardiac pump function (Groden, 1993; Francis & Cohn, 1990). Ecadotril may also be expected to make a favorable impact upon the deleterious process of ventricular remodeling, i.e., thinning and eccentric hypertrophy (dilatation) of the renin-angiotensin- aldosterone hormonal axis. It is also possible, but not yet proven, that by modulating local ANP feedback loops and autocrine effects in the ventricular myocardium, ecadotril may protect the heart from this process of remodeling. This trial is a randomized, double blind, placebo-controlled, parallel arm, forced titration study comparing the additional of ecadotril 50 (then 100 then 200 then 300 then 400) mg BID, or placebo to a background of optimal conventional therapy. There is a 2 week run-in during which single-blind placebo will be added to background treatment with an ACE inhibitor and a diuretic; use of digitalis is optional. There is a forced titration after 2 weeks of each double-blind treatment regiment. The total duration of double-blind treatment is 10 weeks. The patients in the placebo and ecadotril groups will be compared for hemodynamic, biochemical and adverse event variables. A Phase III trial with Ecadotril is planned for the near future. This trial would enroll more than 500 patients with congestive heart failure.
| Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201 |
| Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445 |
| Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247 |
| James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4 |
| Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628 |
| Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417 |
| Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213 |
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17 |
| Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79 |
| Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32 |
Showing the most recent 10 out of 128 publications
